TapImmune Inc. (NASDAQ:MRKR) Receives Average Rating of “Buy” from Analysts

Share on StockTwits

Shares of TapImmune Inc. (NASDAQ:MRKR) have been assigned an average recommendation of “Buy” from the eight analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $10.72.

A number of research firms have recently commented on MRKR. Janney Montgomery Scott cut their target price on TapImmune from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Zacks Investment Research downgraded TapImmune from a “hold” rating to a “sell” rating in a research note on Thursday, October 10th. ValuEngine raised TapImmune from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Piper Jaffray Companies decreased their price objective on TapImmune from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th. Finally, Nomura reissued a “buy” rating and issued a $16.00 price objective on shares of TapImmune in a report on Tuesday, August 13th.

Shares of TapImmune stock opened at $3.00 on Wednesday. The firm has a market capitalization of $144.93 million, a P/E ratio of -1.80 and a beta of 0.11. The company has a quick ratio of 15.83, a current ratio of 15.83 and a debt-to-equity ratio of 0.01. TapImmune has a 52 week low of $2.61 and a 52 week high of $9.17. The firm’s 50 day moving average is $3.64 and its two-hundred day moving average is $5.35.

TapImmune (NASDAQ:MRKR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.01. As a group, research analysts expect that TapImmune will post -0.48 earnings per share for the current fiscal year.

TapImmune Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.

Featured Story: Return on Investment (ROI) Defined, Explained

Analyst Recommendations for TapImmune (NASDAQ:MRKR)

Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.